Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug153 | AVIGAN Wiki | 1.00 |
| drug2935 | Placebo Comparator Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The primary object of this clinical study is to investigate the efficacy of HLCM051 in patients with ARDS caused by pneumonitis.
Description: VFD for 28 days after administration of the investigational product
Measure: Ventilator-free days (VFD)(ARDS caused by pneumonia cohort) Time: 28 days after administration of the investigational productDescription: The number and rate of adverse events
Measure: Adverse events(ARDS caused by COVID-19 cohort) Time: From informed consent to 180 days after administration of the investigational productDescription: Change from baseline in systolic blood pressure(mmHg)
Measure: Change from baseline in systolic blood pressure(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in diastolic blood pressure(mmHg)
Measure: Change from baseline in diastolic blood pressure(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in pulse rate(beats/min)
Measure: Change from baseline in pulse rate(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in respiration(breath/min)
Measure: Change from baseline in respiration(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in oxygen saturation(%)
Measure: Change from baseline in oxygen saturation(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in body temperature(C)
Measure: Change from baseline in body temperature(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in red blood cell count(/uL)
Measure: Change from baseline in red blood cell count(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in hemoglobin(g/dL)
Measure: Change from baseline in hemoglobin(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in hematocrit(%)
Measure: Change from baseline in hematocrit(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in leukocyte count(/uL)
Measure: Change from baseline in leukocyte count(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in neutrophils(%)
Measure: Change from baseline in neutrophils(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in eosinophils(%)
Measure: Change from baseline in eosinophils(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in basophils(%)
Measure: Change from baseline in basophils(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in lymphocytes(%)
Measure: Change from baseline in lymphocytes(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in monocytes(%)
Measure: Change from baseline in monocytes(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in platelet count(/uL)
Measure: Change from baseline in platelet count(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in asparate aminotransferase(AST)(IU/L)
Measure: Change from baseline in asparate aminotransferase(AST)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in alanine aminotransferase(ALT)(IU/L)
Measure: Change from baseline in alanine aminotransferase(ALT)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in alkaline phosphatase(ALP)(IU/L)
Measure: Change from baseline in alkaline phosphatase(ALP)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in total bilirubin(mg/dL)
Measure: Change from baseline in total bilirubin(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in blood urea nitrogen(BUN)(mg/dL)
Measure: Change from baseline in blood urea nitrogen(BUN)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in creatinine(mg/dL)
Measure: Change from baseline in creatinine(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in sodium(Na)(mmol/L)
Measure: Change from baseline in sodium(Na)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in potassium(K)(mmol/L)
Measure: Change from baseline in potassium(K)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in chloride(Cl)(mmol/L)
Measure: Change from baseline in chloride(Cl)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in calcium(Ca)(mg/dL)
Measure: Change from baseline in calcium(Ca)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in blood sugar(mg/dL)
Measure: Change from baseline in blood sugar(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in urinary protein(- to >= 4+)
Measure: Change from baseline in urinary protein(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in urinary sugar(- to >= 4+)
Measure: Change from baseline in urinary sugar(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in uric blood(- to >= 4+)
Measure: Change from baseline in uric blood(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in urinary sediment(RBC)(/HPF)
Measure: Change from baseline in urinary sediment(RBC)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in urinary sediment(WBC)(/HPF)
Measure: Change from baseline in urinary sediment(WBC)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in urinary sediment(Other)(/HPF)
Measure: Change from baseline in urinary sediment(Other)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports